These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20037268)

  • 21. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.
    Ide T; Hino T; Ogata K; Miyajima I; Kuwahara R; Kuhara K; Sata M
    Am J Gastroenterol; 2009 Jan; 104(1):70-5. PubMed ID: 19098852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of age and sex on virologic responses of peginterferon alfa-2a and ribavirin treatment in chronic hepatitis C].
    Yu JW; Sun LJ; Kang P; Zhao YH; Yan BZ; Zhu PF
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1002-7. PubMed ID: 22333166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.
    Rossignol JF; Elfert A; Keeffe EB
    J Clin Gastroenterol; 2010 Aug; 44(7):504-9. PubMed ID: 20048684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.
    Mangia A; Minerva N; Bacca D; Cozzolongo R; Ricci GL; Carretta V; Vinelli F; Scotto G; Montalto G; Romano M; Cristofaro G; Mottola L; Spirito F; Andriulli A
    Hepatology; 2008 Jan; 47(1):43-50. PubMed ID: 18069698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].
    Kim JI; Kim SH; Lee BS; Lee HY; Lee TH; Kang YW; Lee HIe; Kim AN; Nam SW; Park BC; Chae HB; Kim SB; Song IH; Park JY; Kim HS
    Korean J Hepatol; 2008 Dec; 14(4):493-502. PubMed ID: 19119244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for genotype 2 hepatitis C virus infection.
    Nanba S; Ikeda F; Fujioka S; Araki Y; Takaguchi K; Hashimoto N; Seki H; Takaki A; Iwasaki Y; Yamamoto K
    Acta Med Okayama; 2015; 69(4):237-44. PubMed ID: 26289915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients].
    Jung EU; Park JH; Pae KI; Kang SW; Park SJ; Jee SR; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2007 Sep; 13(3):341-8. PubMed ID: 17898550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
    Ferenci P; Laferl H; Scherzer TM; Maieron A; Hofer H; Stauber R; Gschwantler M; Brunner H; Wenisch C; Bischof M; Strasser M; Datz C; Vogel W; Löschenberger K; Steindl-Munda P;
    Gastroenterology; 2010 Feb; 138(2):503-12, 512.e1. PubMed ID: 19909752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
    Kamal SM; El Kamary SS; Shardell MD; Hashem M; Ahmed IN; Muhammadi M; Sayed K; Moustafa A; Hakem SA; Ibrahiem A; Moniem M; Mansour H; Abdelaziz M
    Hepatology; 2007 Dec; 46(6):1732-40. PubMed ID: 17943989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
    Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
    Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.